Recent important clinical trials of drugs in osteoporosis

Expert Opinion on Pharmacotherapy

Volumn 5, Issue 7, 2004, Pages 1635-1638

  Doggrell, Shiela A ^a  

^a Doggrell Biomedical Communications   (New Zealand)

Author keywords

Alendronate; Calcitriol; Cardiac transplantation; Postmenopausal osteoporosis; Secondary osteoporosis; Strontium renelate

Indexed keywords

ALENDRONIC ACID; ALFACALCIDOL; BISPHOSPHONIC ACID DERIVATIVE; CALCITRIOL; CALCIUM; CYCLOSPORIN; ESTROGEN; ETIDRONIC ACID; GLUCOCORTICOID; IMMUNOSUPPRESSIVE AGENT; PAMIDRONIC ACID; PARATHYROID HORMONE; PLACEBO; RALOXIFENE; RISEDRONIC ACID; STRONTIUM; STRONTIUM RANELATE; UNCLASSIFIED DRUG; VITAMIN D;

ARTICLE; BONE MASS; BONE REMODELING; CLINICAL TRIAL; CORTICOSTEROID INDUCED OSTEOPOROSIS; DISEASE SEVERITY; DRUG DOSE REDUCTION; DRUG MECHANISM; ESTROGEN THERAPY; FRAGILITY FRACTURE; HEART TRANSPLANTATION; HUMAN; HYPERCALCEMIA; HYPERCALCIURIA; OSSIFICATION; OSTEOLYSIS; OSTEOPOROSIS; POSTMENOPAUSE OSTEOPOROSIS; PRIMARY OSTEOPOROSIS; SECONDARY OSTEOPOROSIS; VERTEBRA FRACTURE;

AGED; ALENDRONATE; ANIMALS; CALCITRIOL; DRUG THERAPY, COMBINATION; EXERCISE THERAPY; EXPERT TESTIMONY; FEMALE; HEART TRANSPLANTATION; HUMANS; META-ANALYSIS; MIDDLE AGED; ORGANOMETALLIC COMPOUNDS; OSTEOPOROSIS, POSTMENOPAUSAL; RISK ASSESSMENT; THIOPHENES;

EID: 3543117321     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656566.5.7.1635     Document Type: Article

References (16)

1. MEUNIER PJ, ROUX C, SEEMAN E et al.: The effects of strontium ranelate on the risk of vertebral fracture in women with postmenopausal osteoporosis. N. Engl. J. Med. (2004) 350:459-468.
2. SHANE E, ADDESSO V, NAMEROW PB et al.: Alendronate versus calcitriol for the prevention of bone loss after cardiac transplantation. N. Engl. J. Med. (2004) 350:767-776.
3. SIRIUS ES, MILLER PD, BARRETT-CONNOR E et al.: Identification and fracture outcomes of undiagnosed low bone mineral density in postmenopausal women. Results form the National Osteoporosis Risk Assessment. JAMA (2001) 286:2815-2822.
4. MESSINGER-RAPPORT BJ, THACKER HL: Prevention for the older women, part 3: A practical guide to prevention and treatment of osteoporosis. Geriatrics (2002) 57:16-27.
5. EL-HAJJ FG: Strontium ranelate - a novel therapy for osteoporosis or a permutation of the same. N. Engl. J. Med. (2004) 350:504-506.
6. MARIE PJ: Optimizing bone metabolism in osteoporosis: insight into the pharmacological profile of strontium ranelate. 0steoporosis Int. (2003) 14(Suppl. 3):S9-S12.
7. BROWN EM: Is the calcium receptor a molecular target for the actions of strontium on bone? 0steoporos. Int. (2003) 14(Suppl. 3):S25-S34.
8. REGINSTER JY, DEROISY R, DOUGADOS M et al.: Prevention of early postmenopausal loss by strontium ranelate: the randomized, two-year, double-masked, dose-ranging, placebo-controlled PREVOS trial. Osteoporos. Int. (2002) 13:925-931.
9. MEUNIER PJ, SLOSMAN DO, DELMAS PD, et al.: Strontium ranelate: a dose-dependent effects in established postmenopausal vertebral osteoporosis - a 2-year randomized, placebo controlled trial. J. Clin. Endocrinol. Metab. (2002) 87:2060-2066.
10. BLACK DM, GREENSPAN SL, ENSRU KE et al.: The effects of parathyroid hormone and alendronate alone or in combination in post menopausal osteoporosis. N. Engl. J. Med. (2003) 349:1207-1215.
11. FINKELSTEIN JS, HAYES A, HUNZELMAN JL et al.: The effects of parathyroid hormone, alendronate, or both in men with osteoporosis. N. Engl. J. Med. (2003) 349:1216-1226.
12. VAN CLEEMPUT J, DAENEN W, GEUSENS P et al.: Prevention of bone loss in cardiac transplant recipients. A comparison of bisphosphonates and vitamin D. Transplantation (1996) 61:1495-1499.
13. STEMPFLE HU, WERNER C, ECHTLER S et al.: Prevention of osteoporosis after cardiac transplantation: a prospective, longitudinal, randomized, double-blind trial with calcitriol. Transplantation (1999) 68:523-530.
14. SAMBROOK P, HENDERSON NK, KEOGH A et al.: Effect of calcitriol on bone loss after cardiac or lung transplantation. J. Bone Miner. Res. (2000) 15:1818-1824.
15. SHANE E, RODINO MA, MCMAHON DJ et al.: Prevention of bone loss after heart transplantation with antiresorptive therapy: a pilot study. J. Heart. Lung. Transplant. (1998) 17:1089-1096.
16. BRAITH RW, MAGYARI PM, FULTON MN et al.:. Resistance exercise training and alendronate reverese glucocorticoid-induced osteoporosis in heart transplant recipients. J. Heart. Lung. Transplant. (2003) 22:1082-1090.